Clinical Trial Update: Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is assessing SHR2554 in combination with other antitumor therapies for advanced/metastatic gastric cancer and gastroesophageal junction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• SHR2554

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Status: RECRUITING